Literature DB >> 29296940

Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies.

Elias Jabbour1, Hagop Kantarjian1.   

Abstract

Publisher's Note: This article has a companion Counterpoint by Davis and Mackall. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.

Entities:  

Year:  2016        PMID： 29296940      PMCID： PMC5737178          DOI： 10.1182/bloodadvances.2016000042

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  24 in total

1.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

2.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

3.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

4.  Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.

Authors:  Sara Raponi; Maria Stefania De Propris; Stefania Intoppa; Maria Laura Milani; Antonella Vitale; Loredana Elia; Omar Perbellini; Giovanni Pizzolo; Robin Foá; Anna Guarini
Journal:  Leuk Lymphoma       Date:  2011-02-24

Review 5.  Monoclonal antibodies in acute lymphoblastic leukemia.

Authors:  Elias Jabbour; Susan O'Brien; Farhad Ravandi; Hagop Kantarjian
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

6.  Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Stefan Faderl; Susan O'Brien; Carlos Bueso-Ramos; Jorge Cortes; Guillermo Garcia-Manero; Francis J Giles; Srdan Verstovsek; William G Wierda; Sherry A Pierce; Jianqin Shan; Mark Brandt; Fredrick B Hagemeister; Michael J Keating; Fernando Cabanillas; Hagop Kantarjian
Journal:  Cancer       Date:  2006-04-01       Impact factor: 6.860

7.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Authors:  Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William Wierda; Michelle A Detry; Alice Lynn; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

8.  Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Susan O'Brien; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; William Wierda; Farhad Ravandi; Srdan Verstovsek; Jeffrey L Jorgensen; Carlos Bueso-Ramos; Michael Andreeff; Sherry Pierce; Rebecca Garris; Michael J Keating; Jorge Cortes; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

9.  Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.

Authors:  David A Rizzieri; Jeffrey L Johnson; John C Byrd; Gerard Lozanski; Kristie A Blum; Bayard L Powell; Thomas C Shea; Sreenivasa Nattam; Eva Hoke; Bruce D Cheson; Richard A Larson
Journal:  Br J Haematol       Date:  2014-01-15       Impact factor: 6.998

10.  Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.

Authors:  Susan O'Brien; Deborah A Thomas; Farhad Ravandi; Stefan Faderl; Sherry Pierce; Hagop Kantarjian
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860
View more
  3 in total

Review 1.  Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.

Authors:  Mahsa Mohseni; Hasan Uludag; Joseph M Brandwein
Journal:  Am J Blood Res       Date:  2018-12-10

2.  An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia.

Authors:  Jun Ma; Ting Liu; Jie Jin; Jianda Hu; Qifa Liu; Jianxiang Wang; Zhixiang Shen; Xin Du; Bin Jiang; Xianhua Meng
Journal:  Int J Hematol Oncol       Date:  2018-07-25

Review 3.  Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia.

Authors:  Agata Pastorczak; Krzysztof Domka; Klaudyna Fidyt; Martyna Poprzeczko; Malgorzata Firczuk
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.